False Positive Rates of Randomized Phase II Designs
- 1 August 1999
- journal article
- review article
- Published by Elsevier in Controlled Clinical Trials
- Vol. 20 (4) , 343-352
- https://doi.org/10.1016/s0197-2456(99)00009-4
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group BLeukemia, 1998
- Comparison of Patient Characteristics and Outcome Between a Single-Institution Phase II Trial and a Cooperative-Group Phase II Trial with Identical Eligibility in Metastatic MelanomaAmerican Journal of Clinical Oncology, 1997
- Granulocyte Colony-Stimulating Factor (Filgrastim) Accelerates Granulocyte Recovery After Intensive Postremission Chemotherapy for Acute Myeloid Leukemia With Aziridinyl Benzoquinone and Mitoxantrone: Cancer and Leukemia Group B Study 9022Blood, 1997
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- Intraperitoneal Mitoxantrone or Floxuridine: Effects on Time-to-Failure and Survival in Patients with Minimal Residual Ovarian Cancer after Second-Look Laparotomy—A Randomized Phase II Study by the Southwest Oncology GroupGynecologic Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Design and analysis of multiarm clinical trials with survival endpointsControlled Clinical Trials, 1995
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 womenThe Lancet, 1992
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972